Ribavirin treatment for chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C virus (HCV) infection is a significant global health concern.
• Current treatment options for chronic hepatitis C have limitations.
• Non-A, non-B hepatitis, now known as hepatitis C, requires effective therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of oral ribavirin as a treatment for chronic hepatitis C.
• To assess the impact of ribavirin on liver enzyme levels in patients with chronic hepatitis C.
• To determine the potential of ribavirin as an oral therapeutic agent for hepatitis C.

Main Methods:

• Pilot study involving 10 patients with biopsy-proven chronic non-A, non-B hepatitis.
• Patients received oral ribavirin at 1000-1200 mg daily for 12 weeks.
• Serum alanine aminotransferase (ALT) levels were monitored before, during, and after treatment.

Main Results:

• A significant decrease in median ALT levels was observed after 12 weeks of ribavirin treatment (p < 0.005).
• ALT levels returned to pre-treatment concentrations within 6 weeks post-therapy.
• Reported side-effects were mild and reversible upon discontinuation of ribavirin.

Conclusions:

• Oral ribavirin demonstrates potential as an effective treatment for chronic hepatitis C.
• Ribavirin is the first oral drug to show promise in managing chronic hepatitis C.
• Further investigation in controlled trials, potentially combining ribavirin with interferon alpha, is warranted.